D Baralle

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. pmc A prospective study of neurofibromatosis type 1 cancer incidence in the UK
    L Walker
    Department of Medical Genetics, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QQ, UK
    Br J Cancer 95:233-8. 2006
  2. ncbi Different mutations in the NF1 gene are associated with Neurofibromatosis-Noonan syndrome (NFNS)
    Diana Baralle
    Department of Medical Genetics, Addenbrooke s Hospital, Cambridge, United Kingdom
    Am J Med Genet A 119:1-8. 2003
  3. pmc Splicing in action: assessing disease causing sequence changes
    D Baralle
    Department of Medical Genetics, Box 134, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    J Med Genet 42:737-48. 2005
  4. ncbi Functional splicing assay shows a pathogenic intronic mutation in neurofibromatosis type 1 (NF1) due to intronic sequence exonization
    M Raponi
    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Hum Mutat 27:294-5. 2006
  5. pmc hnRNP H binding at the 5' splice site correlates with the pathological effect of two intronic mutations in the NF-1 and TSHbeta genes
    Emanuele Buratti
    International Centre for Genetic Engineering and Biotechnology, 34012 Trieste, Italy
    Nucleic Acids Res 32:4224-36. 2004
  6. pmc Automated comparative sequence analysis identifies mutations in 89% of NF1 patients and confirms a mutation cluster in exons 11-17 distinct from the GAP related domain
    C Mattocks
    Department of Medical Genetics, Box 134, Addenbrooke s Hospital, Cambridge, UK
    J Med Genet 41:e48. 2004
  7. ncbi Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC)
    Jill Yardley
    Academic Unit of Medical Genetics and Regional Genetics Service, St Mary s Hospital, Manchester, United Kingdom
    Invest Ophthalmol Vis Sci 45:3683-9. 2004
  8. ncbi NF1 mRNA biogenesis: effect of the genomic milieu in splicing regulation of the NF1 exon 37 region
    Marco Baralle
    International Centre for Genetic Engineering and Biotechnology, ICGEB, Padriciano 99, 34012 Trieste, Italy
    FEBS Lett 580:4449-56. 2006
  9. ncbi A centrosomal mechanism involving CDK5RAP2 and CENPJ controls brain size
    Jacquelyn Bond
    Molecular Medicine Unit, University of Leeds, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Nat Genet 37:353-5. 2005
  10. ncbi PMS2 mutations in childhood cancer
    Michel De Vos
    University of Leeds, Yorkshire Regional Genetics Service, United Kingdom
    J Natl Cancer Inst 98:358-61. 2006

Collaborators

  • M Upadhyaya
  • B Ponder
  • D Thompson
  • E R Maher
  • Jacquelyn Bond
  • Charles ffrench-Constant
  • Marco Baralle
  • Emanuele Buratti
  • Michela Raponi
  • Michel De Vos
  • M Raponi
  • L Walker
  • Laura De Conti
  • Francisco E Baralle
  • C Mattocks
  • Jill Yardley
  • John R Yates
  • Natasa Skoko
  • D Easton
  • Jill R Mann
  • Julia Rankin
  • Anna Knezevich
  • Dario Motti
  • Eamonn Sheridan
  • M Ponder
  • Adam W Glaser
  • Graham R Taylor
  • Ruth Charlton
  • Bruce E Hayward
  • Trevor R Cole
  • Madhuri Bhuvanagiri
  • I Frayling
  • David T Bonthron
  • Susan Picton
  • Carole M E McKeown
  • Bernard Puech
  • Jean Jacques De Laey
  • M Bobrow
  • Maurizio Romano
  • Graeme C M Black
  • Philippe Kestelyn
  • Ludwine M Messiaen
  • P Tarpey
  • Youhna M Ayala
  • Bart Loeys
  • J Whittaker
  • Niki Hart-Holden
  • Bart P Leroy
  • M Ashwin Reddy
  • Anthony T Moore
  • Elias Traboulsi
  • Rahat Perveen
  • Forbes D C Manson
  • Shomi S Bhattacharya
  • Bart A Lafaut

Detail Information

Publications11

  1. pmc A prospective study of neurofibromatosis type 1 cancer incidence in the UK
    L Walker
    Department of Medical Genetics, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QQ, UK
    Br J Cancer 95:233-8. 2006
    ..27). The most frequent types of cancer were connective tissue (14% risk by age 70, 95% CI 7.8-24%) and brain tumours (7.9, 95% CI 3.9-16%). There was no statistically significant excess of cancers at other sites (P=0.22)...
  2. ncbi Different mutations in the NF1 gene are associated with Neurofibromatosis-Noonan syndrome (NFNS)
    Diana Baralle
    Department of Medical Genetics, Addenbrooke s Hospital, Cambridge, United Kingdom
    Am J Med Genet A 119:1-8. 2003
    ..These results show that NFNS can in some cases result from different mutations in the NF1 gene and therefore represents a variant form of NF1...
  3. pmc Splicing in action: assessing disease causing sequence changes
    D Baralle
    Department of Medical Genetics, Box 134, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    J Med Genet 42:737-48. 2005
    ..The fact that human pathology can provide pointers to new modulatory elements of splicing should be exploited...
  4. ncbi Functional splicing assay shows a pathogenic intronic mutation in neurofibromatosis type 1 (NF1) due to intronic sequence exonization
    M Raponi
    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Hum Mutat 27:294-5. 2006
    ..Significantly an additional single nucleotide change disrupting the cryptic 5'ss consensus sequence rescues the effect of the pathogenetic mutation resulting in normal splicing...
  5. pmc hnRNP H binding at the 5' splice site correlates with the pathological effect of two intronic mutations in the NF-1 and TSHbeta genes
    Emanuele Buratti
    International Centre for Genetic Engineering and Biotechnology, 34012 Trieste, Italy
    Nucleic Acids Res 32:4224-36. 2004
    ..Thus, the reason why similar nucleotide substitutions can be either neutral or very disruptive of splicing function can be explained by the presence of specific binding signatures depending on local contexts...
  6. pmc Automated comparative sequence analysis identifies mutations in 89% of NF1 patients and confirms a mutation cluster in exons 11-17 distinct from the GAP related domain
    C Mattocks
    Department of Medical Genetics, Box 134, Addenbrooke s Hospital, Cambridge, UK
    J Med Genet 41:e48. 2004
  7. ncbi Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC)
    Jill Yardley
    Academic Unit of Medical Genetics and Regional Genetics Service, St Mary s Hospital, Manchester, United Kingdom
    Invest Ophthalmol Vis Sci 45:3683-9. 2004
    ..To investigate the genetic basis of autosomal dominant vitreoretinochoroidopathy (ADVIRC), a rare, inherited retinal dystrophy that may be associated with defects of ocular development, including nanophthalmos...
  8. ncbi NF1 mRNA biogenesis: effect of the genomic milieu in splicing regulation of the NF1 exon 37 region
    Marco Baralle
    International Centre for Genetic Engineering and Biotechnology, ICGEB, Padriciano 99, 34012 Trieste, Italy
    FEBS Lett 580:4449-56. 2006
    ..This is a unique example of what may be a more general phenomena involved in the tuning of pre-mRNA processing and gene expression modulation in the chromosomal setting...
  9. ncbi A centrosomal mechanism involving CDK5RAP2 and CENPJ controls brain size
    Jacquelyn Bond
    Molecular Medicine Unit, University of Leeds, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Nat Genet 37:353-5. 2005
    ....
  10. ncbi PMS2 mutations in childhood cancer
    Michel De Vos
    University of Leeds, Yorkshire Regional Genetics Service, United Kingdom
    J Natl Cancer Inst 98:358-61. 2006
    ..This cancer syndrome can be mistaken for neurofibromatosis type 1, with important management implications including the risk of the disorder occurring in siblings and the likelihood of tumor development in affected individuals...
  11. doi Can donor splice site recognition occur without the involvement of U1 snRNP?
    Michela Raponi
    Human Genetics Division, University of Southampton, Duthie Building Mailpoint 808, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK
    Biochem Soc Trans 36:548-50. 2008
    ..We suggest that, in clinical molecular genetics, it is important to evaluate sequence variants for aberrant splicing even in those cases where the variant is not thought to alter the U1 snRNA interaction...